Transcatheter arterial chemoembolization using raltitrexed and lobaplatin for advanced hepatocellular carcinoma
10.3760/cma.j.issn.1007-631X.2017.09.014
- VernacularTitle:雷替曲塞联合洛铂经肝动脉灌注化疗栓塞治疗中晚期肝癌
- Author:
Hengfei MA
1
;
Xuegang YANG
;
Lingjun LI
;
Huixian MA
;
Huina ZHOU
;
Jingjing LYU
;
Guohui XU
Author Information
1. 平顶山市第一人民医院介入科
- Keywords:
Carcinoma,hepatocellular;
Antineoplastic combined chemotherapy protocols;
Raltitrexed
- From:
Chinese Journal of General Surgery
2017;32(9):766-769
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of transcatheter arterial chemoemblization (TACE) using raltitrexed and lobaplatin in treating advanced hepatocellular carcinoma (HCC).Methods From March 2009 to November 2014,95 cases were treated by raltitrexed combined with lobaplatin (raltitrexed group) through TACE and 124 cases by fluorouracil combined with oxaliplatin (fluorouracil group) through TACE.Disease control rate (DCR),median progression-free survival (mPFS) time and median overall survival (mOS) time were compared between the two groups.Survival rate were analyzed using Kaplan-Meier method and Log-rank analysis in SPSS 16.0.Results The disease control rate of raltitrexed group was 91.6％ (87/95),compared with fluorouracil group of 84.6％ (105/124) in fluorouracil group (x2 =2.505,P =0.474).The mPFS of raltitrexed group was 6.8 months and that of fluorouracil group was 5.9 months (x2 =5.542,P =0.019);mOS of raltitrexed group was 13.6 months and fluorouracil group was 11.4 months (x2 =5.953,P =0.015).The main adverse reactions in the two groups were not statistically significant (P ＞ 0.05).Conclusions TACE using rahitrexed and oxaliplatin prolongs the progression free survival and overall survival time of patients with advanced hepatic carcinoma.
